Your session is about to expire
← Back to Search
Uproleselan + Cladribine + Cytarabine for Acute Myeloid Leukemia
Study Summary
This trial is testing a combination of three drugs to treat secondary acute myeloid leukemia. The drugs work in different ways to stop the growth of cancer cells.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have been treated with uproleselan before.I do not have acute promyelocytic leukemia (AML-M3).I am using contraception and will continue to do so during the study.I do not have any severe illnesses that my doctor says could interfere with the study.I am not pregnant or breastfeeding.I have secondary AML and haven't been treated for it yet.You have a known allergy to any of the ingredients in the chemotherapy treatment.I am 18 years old or older.I can take care of myself but might not be able to do heavy physical work.I understand the study's requirements and have signed the consent form.My AML cancer developed from a previous blood disorder treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
- Group 1: Treatment (uproleselan, cladribine, cytarabine)
- Approved for 5 Other Conditions - This treatment demonstrated efficacy for 5 other conditions.
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Frequently Asked Questions
What is the current enrolment size for this experiment?
"Affirmative. According to the data available on clinicaltrials.gov, this study is currently seeking volunteers for participation. The medical trial was first published on June 11th 2021 and most recently updated on June 25th 2021. 37 individuals are expected to take part in the investigation from a single site of recruitment."
Are there vacancies for participants in this clinical research endeavor?
"As indicated by the clinicaltrials.gov portal, this research project is still open for recruitment. The original post was uploaded on June 11th 2021 and its information most recently revised on June 25th 2021."
Could you elaborate on the prior investigations into Uproleselan?
"Currently, there are 255 ongoing experiments into Uproleselan with 67 trials in their final stages. Although the majority of these studies originate from New york City, globally there are 10161 sites conducting research on this medication."
What health conditions is Uproleselan typically prescribed for?
"Uproleselan is primarily prescribed to treat stage 1 protein, human. However, it can also be beneficial for those suffering from hairy cell leukemia, multiple sclerosis and prophylaxis of meningeal leukemia."
Share this study with friends
Copy Link
Messenger